Dr. Ellis on Potential Impact of CDK4/6 Inhibitors in Breast Cancer

Matthew J. Ellis, MD, PhD
Published: Thursday, Mar 16, 2017



Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

In metastatic disease, the addition of a CDK4/6 inhibitor has shown a benefit in delaying disease progression in trials. But, Ellis adds, the question that remains is do these drugs—ribociclib (Kisqali), palbociclib (Ibrance), and abemaciclib—improve overall survival.

Another question is whether these drugs will improve outcome in early disease. Not all patients benefit from CDK4/6 inhibitors, and other avenues such as neoadjuvant endocrine therapy or genomic models may be more beneficial for that subset.

According to Ellis, current trials are too immature to give definite answers to these questions.

<<< View more from the St. Gallen's Breast Cancer Conference


Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

In metastatic disease, the addition of a CDK4/6 inhibitor has shown a benefit in delaying disease progression in trials. But, Ellis adds, the question that remains is do these drugs—ribociclib (Kisqali), palbociclib (Ibrance), and abemaciclib—improve overall survival.

Another question is whether these drugs will improve outcome in early disease. Not all patients benefit from CDK4/6 inhibitors, and other avenues such as neoadjuvant endocrine therapy or genomic models may be more beneficial for that subset.

According to Ellis, current trials are too immature to give definite answers to these questions.

<<< View more from the St. Gallen's Breast Cancer Conference

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x